Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04565795 · ClinicalTrials.gov registry record · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
A NA study of Ureteral Diseases, sponsored by Adva-Tec.
- Recruiting
- Registry status
- NA
- Development phase
- 87
- Enrollment target
- 4
- Study locations
NCT04565795 is a NA study of Ureteral Diseases that is actively recruiting participants, run by Adva-Tec. The registered enrollment target is 87 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT04565795, a NA study of Ureteral Diseases, is actively recruiting participants, sponsored by Adva-Tec.
- RECRUITING
- Registry status
- NA
- Development phase
- 87 participants
- Enrollment target
- 4
- Study locations
Study Summary
A prospective, multi-center, non-randomized trial to demonstrate safety and device performance of the ADVA-Tec Uriprene® Degradable Temporary Ureteral Stent.
Conditions Studied
Interventions
- DEVICE Uriprene® Degradable Temporary Ureteral Stent
Study Locations (4)
Arizona
- Mayo Clinic Arizona - Phoenix
California
- University of California Los Angeles - Los Angeles
Florida
- University of Florida - Gainesville
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2026-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04565795
The ClinicalTrials.gov registry entry for NCT04565795 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adva-Tec, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ureteral Diseases appearing as the primary indexed condition, and to 1 intervention - of which Uriprene® Degradable Temporary Ureteral Stent is the first listed.
NCT04565795 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04565795 about?
NCT04565795 is a clinical study titled "Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy". A prospective, multi-center, non-randomized trial to demonstrate safety and device performance of the ADVA-Tec Uriprene® Degradable Temporary Ureteral Stent.
What is the current status of trial NCT04565795?
This trial is currently recruiting. It is a NA study. The enrollment target is 87 participants. The study started on 2022-07-01. Estimated completion is 2026-09.
What conditions does trial NCT04565795 study?
This clinical trial studies the following conditions: Ureteral Diseases.
What interventions are being tested in trial NCT04565795?
The interventions under investigation include: Uriprene® Degradable Temporary Ureteral Stent (DEVICE).
Who is sponsoring clinical trial NCT04565795?
This trial is sponsored by Adva-Tec, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04565795 being conducted?
This trial has 4 study locations across Arizona, California, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ureteral Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.